NYSE: LHLabcorp Holdings Inc Stock
$246.27+3.90 (+1.61%)
Updated May 15, 2025
LH Price
$246.27
Fair Value Price
N/A
Market Cap
$20.61B
52 Week Low
$191.97
52 Week High
$258.59
P/E
28.24x
P/B
2.48x
P/S
1.48x
PEG
0.93x
Dividend Yield
0.58%
Revenue
$13.18B
Earnings
$730.80M
Gross Margin
27.9%
Operating Margin
8.76%
Profit Margin
5.5%
Debt to Equity
1.12
Operating Cash Flow
$2B
Beta
0.63
Next Earnings
N/A
Ex-Dividend
May 29, 2025
Next Dividend
Jun 11, 2025
LH Overview
Laboratory Corporation of America Holdings, a clinical laboratory company, offers tests (blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests). The company also provides gene-based and esoteric testing, and advanced tests targeting specific diseases. LabCorp was founded in 1971 and is headquartered in Burlington, NC.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
LH
Ranked#11 of 43
Ranked#11 of 43
Be the first to know about important LH news, forecast changes, insider trades & much more!
LH News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LH ($246.27) is trading above its intrinsic value of $136.21, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LH is poor value based on its earnings relative to its share price (28.24x), compared to the US market average (26.06x)
P/E vs Market Valuation
LH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more LH due diligence checks available for Premium users.
Valuation
LH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28.24x
Industry
19.87x
Market
26.06x
LH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LH is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
LH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.48x
Industry
3.36x
LH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LH price to earnings growth (PEG)
For valuing profitable companies with growth potential
LH is good value based... subscribe to Premium to read more.
PEG Value Valuation
LH's financial health
Profit margin
Revenue
$3.3B
Net Income
$212.8M
Profit Margin
6.4%
LH's Earnings (EBIT) of $1.15B... subscribe to Premium to read more.
Interest Coverage Financials
LH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.6B
Liabilities
$9.3B
Debt to equity
1.12
LH's short-term assets ($3.79B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LH's long-term liabilities ($7.22B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$18.5M
Investing
-$336.0M
Financing
-$839.7M
LH's operating cash flow ($1.63B)... subscribe to Premium to read more.
Debt Coverage Financials
LH vs Diagnostic & Research Stocks
Labcorp Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.